Carta PAYBACK di Mondadori
Su Mondadori Store, con la tua carta PAYBACK ti premi ad ogni acquisto.
»
English
»
Scienza e Tecnica
»
Medicina
Edward C. Stites
-
Kendra Paskvan
-
Shumei Kato
pubblicato da
Cambridge University Press
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
Scrivi una recensione per "Therapeutic Targeting of RAS Mutant Cancers"
Torna in cima
Leggi un estratto
dai un voto
